 | Up a level |
2020
Lin, C. C., Joerger, M., Grell, P., Chiappori, A. A., Leal, T. A., Kasper, S., Jerusalem, G., Goncalves, A., Wolf, J., De Braud, F., de Jonge, M. J. A., Otero, J., Chhagan, S., Cipolletta, D., Morris, E., Chowdhury, N. R., Hurtado, F. K. and Tan, D. S. (2020). Continuous vs intermittent adenosine 2A receptor (A2AR) inhibition in preclinical colon cancer (CC) models and in a Phase (Ph) II study of taminadenant (NIR178) + spartalizumab (PDR001) in patients ( pts) with non-small cell lung cancer (NSCLC). Eur. J. Cancer, 138. S. S12 - 2. OXFORD: ELSEVIER SCI LTD. ISSN 1879-0852
2018
Wolf, J., Seto, T., Han, J-Y., Reguart, N., Garon, E. B., Groen, H. J. M., Tan, D. S., Hida, T., de Jonge, M. J. A., Orlov, S. V., Smit, E. F., Souquet, P-J., Vansteenkiste, J. F., Giovannini, M., Le Mouhaer, S., Robeva, A., Waldron-Lynch, M. and Heist, R. S. (2018). Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with MET Delta ex14 mutated advanced non-small cell lung cancer (NSCLC). Ann. Oncol., 29. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041